Evidence map›Paper›PMID 23478748›Full record

Trial reportMolecular psychiatry2014

Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.

S Smesny, B Milleit, U-C Hipler, C Milleit, M R Schäfer, C M Klier, M Holub, I Holzer, G E Berger, M Otto and 5 more

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Molecular psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 7 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 7 syntheses or guidelines pooled it, 80 citations in OpenAlex.

  1. Nutraceuticals in Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2024
    Pooled it
  2. Effects of Omega 3 Fatty Acids on Main Dimensions of Psychopathology.International journal of molecular sciences · 2020
    Pooled it
  3. Interventions for prodromal stage of psychosis.The Cochrane database of systematic reviews · 2019
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Antioxidants (Basel, Switzerland) · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 4 countries.

S SmesnyDepartment of Psychiatry, University Hospital Jena, Jena, Germany.
B MilleitDepartment of Psychiatry, University Hospital Jena, Jena, Germany.
U-C HiplerDepartment of Dermatology, University Hospital Jena, Jena, Germany.
C Milleit1] Department of Psychiatry, University Hospital Jena, Jena, Germany [2] Department of Dermatology, University Hospital Jena, Jena, Germany.
M R Schäfer1] Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria [2] Orygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC, Australia.
C M KlierDepartment of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria.
M HolubDepartment of Nutritional Sciences, University of Vienna, Vienna, Austria.
I HolzerDepartment of Nutritional Sciences, University of Vienna, Vienna, Austria.
G E BergerDepartment of Adolescent Psychiatry Winterthur-Zürcher Unterland, Switzerland.
M OttoDepartment of Psychiatry, University Hospital Jena, Jena, Germany.
I NenadicDepartment of Psychiatry, University Hospital Jena, Jena, Germany.
M Berk1] Orygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC, Australia [2] Deakin University of Melbourne, School of Medicine, Barwon Health, Geelong, VIC, Australia [3] Florey Institute for Neuroscience and Mental Health, Melbourne, VIC, Australia.
P D McGorryOrygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC, Australia.
H SauerDepartment of Psychiatry, University Hospital Jena, Jena, Germany.
G P Amminger1] Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria [2] Orygen Youth Health Research Centre, University of Melbourne, Melbourne, VIC, Australia.
Jena University Hospital · DEMedical University of Vienna · ATUniversity of Melbourne · AUUniversity of Vienna · ATIntegrierte Psychiatrie Winterthur · CHOrygen Youth Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of an ultra-high risk (UHR) profile for psychosis and a greater understanding of its prodrome have led to increasing interest in early intervention to delay or prevent the onset of psychotic illness. In a randomized placebo-controlled trial, we have identified long-chain ω-3 (ω-3) polyunsaturated fatty acid (PUFA) supplementation as potentially useful, as it reduced the rate of transition to psychosis by 22.6% 1 year after baseline in a cohort of 81 young people at UHR of transition to psychosis. However, the mechanisms whereby the ω-3 PUFAs might be neuroprotective are incompletely understood. Here, we report on the effects of ω-3 PUFA supplementation on intracellular phospholipase A2 (inPLA(2)) activity, the main enzymes regulating phospholipid metabolism, as well as on peripheral membrane lipid profiles in the individuals who participated in this randomized placebo-controlled trial. Patients were studied cross-sectionally (n=80) and longitudinally (n=65) before and after a 12-week intervention with 1.2 g per day ω-3 PUFAs or placebo, followed by a 40-week observation period to establish the rates of transition to psychosis. We investigated inPLA(2) and erythrocyte membrane FAs in the treatment groups (ω-3 PUFAs vs placebo) and the outcome groups (psychotic vs non-psychotic). The levels of membrane ω-3 and ω-6 PUFAs and inPLA(2) were significantly related. Some of the significant associations (that is, long-chain ω-6 PUFAs, arachidonic acid) with inPLA(2) activity were in opposite directions in individuals who did (a positive correlation) and who did not (a negative correlation) transition to psychosis. Supplementation with ω-3 PUFA resulted in a significant decrease in inPLA(2) activity. We conclude that ω-3 PUFA supplementation may act by normalizing inPLA(2) activity and δ-6-desaturase-mediated metabolism of ω-3 and ω-6 PUFAs, suggesting their role in neuroprogression of psychosis.

Indexed as

AdolescentAdultCross-Sectional StudiesDisease ProgressionDouble-Blind MethodErythrocyte MembraneFatty Acids, Omega-3Fatty Acids, Omega-6FemaleHumansIntracellular FluidLongitudinal StudiesMalePhospholipases A2Psychotic DisordersRisk FactorsFatty Acids, Omega-3Fatty Acids, Omega-6Phospholipases A2

Identifiers

PMID23478748
OpenAlexW2042927703

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.